Alembic Pharma successfully completes ANVISA, Brazil GMP audit for API-III facility at Karakhadi

Written by Ruchika Sharma Published On 2023-03-25T12:07:44+05:30 | Updated On 25 March 2023 6:37 AM GMT

Alembic Pharma successfully completes ANVISA, Brazil GMP audit for API-III facility at Karakhadi

Vadodara: Alembic Pharmaceuticals Limited has announced that the Company has successfully completed the Brazilian Health Regulatory Agency (ANVISA) GMP audit at API-III Facility at Karakhadi without any observations for its 56 APIs.

The inspection was conducted from 20th March, 2023 to 24th March, 2023.

Headquartered in Vadodara, Gujarat, Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. The company was founded in 1907. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic has a cumulative total of 183 ANDA approvals (160 final approvals and 23 tentative approvals) from USFDA.

Ruchika Sharma

M.Com

Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751